On June 26, 2026, the FDA updated the label for Xeomin, a botulinum toxin injection, to specifically include children and adolescents aged two and older who have upper limb spasticity associated with cerebral palsy.
If that sounds like a small regulatory footnote, it's worth understanding why it isn't. Label language determines what a manufacturer may promote, and it often shapes what insurers will approve. A treatment that has been used in pediatric cerebral palsy care for years now carries explicit approval naming that population.
But a label change is also a good moment for a clear eyed conversation about what botulinum toxin actually does for a child with cerebral palsy, what it doesn't do, and where it fits alongside everything else in a treatment plan. Injections are not a small decision, and the honest answer to what they accomplish is more specific than most families are told.
“Reducing tone is not the goal. It is the window. What gets built inside that window is what changes a child's day.”
— Cerebral Palsy Center Editorial Team
What actually changed
Xeomin is the brand name for incobotulinumtoxinA, made by Merz Therapeutics. It already carried an indication for pediatric upper limb spasticity. However, the June 2026 update expands that indication to specifically cover children and adolescents two years of age and older with spasticity associated with cerebral palsy.
Merz described the change as expanding the opportunity to treat pediatric upper limb spasticity in patients with cerebral palsy, and framed it around the reality that spasticity care is long term management rather than a single intervention. This is both accurate and should be the part families pay attention to most.
The label is for the arm. Upper limb spasticity means the muscles of the shoulder, elbow, forearm, wrist and hand. Lower limb spasticity, which affects walking, is a separate question with its own evidence and its own approvals.
What spasticity is, and why the arm matters
Spasticity is a velocity dependent increase in muscle tone. In plain terms, the faster you try to move a limb, the more it resists. It comes from the way the injured brain sends signals to the muscles, and it is one of the defining features of spastic cerebral palsy, the most common type.
In the arm, spasticity often produces a familiar posture: the elbow bent, the forearm turned palm down, the wrist flexed, and the thumb tucked into the palm. That posture makes ordinary things hard. Getting a sleeve on. Holding a cup with the other hand while the affected arm helps. Keeping the palm clean and dry. Positioning the hand well enough to use it at all.
Left unmanaged over years, persistent spasticity can lead to contracture, where the muscle and surrounding tissue shorten permanently. That is the outcome much of spasticity management is trying to prevent.
How botulinum toxin works
Botulinum toxin blocks the chemical signal that tells a muscle to contract, at the junction between nerve and muscle. Injected in small, targeted amounts into specific overactive muscles, it reduces tone in those muscles while leaving others alone.
The effect is temporary. It typically begins within days to a couple of weeks, peaks over the following weeks, and wears off over roughly three to four months as the nerve terminals recover. Repeat injections are the norm, which is exactly why the manufacturer's own language emphasizes long term management.
What it does, realistically
Botulinum toxin reduces tone in the injected muscles. That is the thing it reliably does.
What that reduction buys depends entirely on what happens next. The window of reduced tone is an opportunity: it is easier for a therapist to stretch the muscle, easier to fit and tolerate a splint or serial cast, and easier for a child to practice a movement that spasticity was blocking. Clinicians commonly pair injections with an intensive block of occupational therapy for this reason.
It also has clear value for comfort and care even when function does not change much. Reducing tone can ease pain, improve hygiene in a tightly closed hand, and make dressing manageable. Those are legitimate goals in their own right and worth stating to your care team if they are what matter most to your family.
What these toxins don't do
It does not treat cerebral palsy. Cerebral palsy comes from an injury to the developing brain, and nothing injected into a muscle changes that injury.
It does not build strength. Reducing tone in an overactive muscle can unmask weakness underneath that was previously hidden by stiffness. That surprises families sometimes, and it is a normal part of the picture.
It doesn't provide permanent relief. When people describe injections as wearing off, nothing has gone wrong. That is how the drug works.
And it isn't a substitute for therapy. An injection without a plan for the months that follow is a missed opportunity.
Where it sits among the other options
Spasticity management in cerebral palsy is a layered field, and injections occupy a specific place in it:
- Physical and occupational therapy remain the foundation and continue regardless of what else is added. See our pages on occupational therapy and physical therapy.
- Orthotics, splinting and serial casting hold a muscle at length over time and often pair directly with injections.
- Oral medications such as baclofen act on the whole body rather than selected muscles, which is useful for widespread spasticity but can bring drowsiness. See our overview of medications.
- Botulinum toxin injections are focal and temporary, best when a small number of specific muscles are the problem.
- Intrathecal baclofen pumps deliver medication directly to the spinal fluid for severe generalized spasticity.
- Selective dorsal rhizotomy is a neurosurgical procedure that permanently reduces spasticity in the legs for carefully selected children.
Choosing among these is a genuine clinical judgment based on which muscles are involved, the child's age, goals, and what has already been tried.
Safety information families should know
All botulinum toxin products carry a boxed warning about the possibility of effects spreading beyond the injection site, which can cause swallowing and breathing difficulties. This is rare, and it is the reason injections are done by clinicians experienced in this specific use.
Reported common side effects in pediatric upper limb patients aged 2 to 17 include upper respiratory infections, nasal congestion, sore throat, runny nose, bronchitis, seizures and dry mouth. Any new swallowing difficulty, breathing difficulty, unusual weakness, drooping eyelids or slurred speech after an injection should prompt an immediate call to your doctor.
Questions worth bringing to the appointment
- Which specific muscles are you proposing to inject, and what problem is each one causing?
- What is the goal we are aiming at, and how will we know in three months whether we hit it?
- What therapy, splinting or casting will happen during the window while tone is reduced?
- How many treatment cycles do you expect before we reassess the overall strategy?
- Is my child a candidate for anything more durable, and if not, why not?
A label update is a good headline. The better outcome for your child comes from what gets built around the injection, not the injection alone.
This article is general health information and not medical advice. Treatment decisions belong to you and your child's physician.
